Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: primary results from cohort B (CPS less-than 1) of the TACTI-003 study
Authors
Metcalf, RobertLaban, S.
Kristensen, C. A.
Ciuleanu, T. E.
Braña, I.
Rivas, A. S.
Dieter, S. M.
Bols, A.
Forster, M. D.
Covela, M. R.
Christian, J.
Vogl, F. D.
Mueller, C.
Triebel, F.
Affiliation
Oncology Deptartment, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2024
Metadata
Show full item recordCitation
Metcalf R, Laban S, Kristensen CA, Ciuleanu TE, Braña I, Rivas AS, et al. Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study. ANNALS OF ONCOLOGY. 2024 AUG;35(8):754-5. PubMed PMID: WOS:001343513200002. English.Journal
Annals of OncologyDOI
10.1016/j.annonc.2024.06.012Additional Links
https://dx.doi.org/10.1016/j.annonc.2024.06.012Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2024.06.012